Trends in the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis following implementation of national HPV vaccination initiatives: a systematic review.

BACKGROUND

Infection with human papillomavirus (HPV) low-risk type 6 and 11 in the respiratory tract can cause recurrent benign squamous papillomas in the larynx, in children, juvenile-onset recurrent respiratory papillomatosis (JoRRP).

OBJECTIVES

This systematic review investigated the impact of national HPV vaccination programs on JoRRP incidence and prevalence.

METHODS

PubMED was systematically searched for publications between 2010 and March 2024 that assessed the incidence and prevalence of JoRRP post-implementation of HPV vaccination programs.

RESULTS

Four studies met the inclusion criteria, comprising 622 patients with JoRRP (range 15-576) from Australia, New Zealand and the Unites States. The majority were girls (F:M ratio 2:1), with a median debut age between three to four years. Two studies ( = 591) showed a significant decline in JoRRP incidence after vaccination from 2,0 per 100,000 < 18 years (2004-2005) to 0,5 per 100,000 < 18 years (2012-2013) in the United States, and 0,16 per 100,000 < 15 years (2012) to 0,02 per 100,000 < 15 years (2016) in Australia. Higher vaccination coverage correlated with a reduced JoRRP burden.

CONCLUSION

Our findings indicate implementation of HPV-vaccination programs reduced the JoRRP incidence and prevalence emphasizing the importance of large-scale HPV vaccination. Total impact of HPV vaccination will become fully evident when the vaccinated population reach childbearing ages.